Clinical trial failures

Sponsor hub

Boehringer Ingelheim clinical trial failures

Review 98 stopped clinical trials from Boehringer Ingelheim, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 2 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials98
Likely biological signals2
Shown below98

Dominant stop reasons

OTHER/UNKNOWN
53
OPERATIONAL
43
EFFICACY/FUTILITY
1
SAFETY
1

Notable sponsors

Boehringer Ingelheim
98

Related phases

Phase I
52
Phase II
32
Phase III
10
Phase IV
4

Crawlable stopped-trial records

Open Explore

Showing up to 98 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT03483077: This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Phase I Healthy trial by Boehringer Ingelheim. Stop reason: OPERATIONAL.

The trial was ended after completion of dose group 6 of the SRD part, in accordance with a predefined protocol discontinuation criteria. The planned bioavailability evaluation was not performed due to the sponsor's decision.